Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Daromun + Lomustine |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Daromun | L19-IL2/L19-TNF-alpha|Darleukin/Fibromun|L19IL2/L19TNF | Daromun consists of a mixture of darleukin, a recombinant IL2 linked to the fibronectin extra domain B (EDB) targeting single-chain variable fragment (L19), and fibromun, a human TNF-alpha linked to L19, which binds to cells expressing fibronectin EDB in tumor neovasculature, potentially resulting in the induction of antitumor immune response against tumor cells expressing EDB-containing fibronectin (NCI Drug Dictionary). | ||
| Lomustine | Belustine | CCNU |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|